Rady Elaraby

Dr. Rady Elaraby

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Gene Reports
Verified
Journal Article
Closed access
FFFatma A. Fathy.ELmougy
Fatma A. Fathy.ELmougy
RMReham A. Mohamed
Reham A. Mohamed
MHMona M. Hassan
Mona M. Hassan
SESuzan M. Elsheikh
Suzan M. Elsheikh
RMRaghda N. Marzban
Raghda N. Marzban
RERady Elaraby
Rady Elaraby

1 January 2025 in Aging and disease
Verified
Journal Article
Open access
PDF file
RERady Elaraby
Rady Elaraby
QTQisheng Tu
Qisheng Tu
YXYing Xie
Ying Xie
TATarek Aboushousha
Tarek Aboushousha
ZLZhongyu Li
Zhongyu Li
JCJake Chen
Jake Chen
Type 2 diabetes (T2D) is a widespread health condition both in the United States and around the world, with insulin resistance playing a critical role in its development. Effective treatment strategies are essential for managing T2D and mitigating associated risks. Adiponectin (APN), secreted by adipocytes, exhibits an inverse correlation with obesity-related adiposity, and its levels are negatively associated with insulin resistance and body mass index. This study aimed to enhance endogenous APN levels in a diet-induced obese (DIO) mouse model using lipid nanoparticles (LNP) as safe delivery agents for APN mRNA conjugates. The results indicate that APN-mRNA-LNP administration successfully induced APN synthesis in various tissues, including muscle, liver, kidney, pancreas, and adipose cells. This induction was associated with several positive outcomes, such as preventing diet-induced body weight gain, improving hyperglycemia by promoting Glut-4 expression, alleviating diabetic nephropathy symptoms by blocking the EGFR pathway, and reducing pro-inflammatory cytokine production. In addition, the treatment demonstrated enhanced insulin sensitivity by activating DGKd and inhibiting PKCε. This resulted in reactivation of insulin receptors in insulin target tissues and stimulation of insulin secretion from pancreatic beta cells. The findings of the present study highlight the potential of APN-mRNA-LNP-based nucleic acid therapy as a treatment for type 2 diabetes, offering a comprehensive approach to addressing its complexities.

18 July 2019 in Cancer Gene Therapy
Verified
Journal Article
Closed access
RERady Elaraby
Rady Elaraby
MKMahmoud A. Khalifa
Mahmoud A. Khalifa
MZMona M. Zoheiry
Mona M. Zoheiry
MZManal Y. Zahran
Manal Y. Zahran
MRMohamed I. Rady
Mohamed I. Rady
FEFaiza M. Essawy
Faiza M. Essawy

27 February 2023 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
SYSamar Samir Youssef
Samar Samir Youssef
RERady Elaraby
Rady Elaraby
EAEman Abd El-Razek Abbas
Eman Abd El-Razek Abbas
MHMohamed Hassany
Mohamed Hassany
TETamer Elbaz
Tamer Elbaz
Circulating cell-free DNA (cfDNA) is a noninvasive substitute to liver biopsy for hepatocellular carcinoma (HCC) molecular profiling. This study aimed to use cfDNA to investigate copy number variat...

13 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
YXYing Xie
Ying Xie
QMQian Ma
Qian Ma
JWJinghao Wang
Jinghao Wang
ZZZoe Xiaofang Zhu
Zoe Xiaofang Zhu
RERady Elaraby
Rady Elaraby
JCJake Chen
Jake Chen
Adiponectin (APN) is a secreted adipokine that plays a key role in modulating energy and bone metabolism, as well as regulating inflammatory responses. The overexpression of APN has been proposed as a potential therapeutic strategy for treating obesity and related disorders. Lipid nanoparticles (LNPs) are promising vectors for transporting messenger ribonucleic acid (mRNA) molecules. This study tested whether delivering a stabilized version of adiponectin mRNA (APN mRNA) using lipid nanoparticles could reduce fat formation and promote bone repair in vitro and in vivo. We demonstrated that transfection with APN-LNP upregulated the mRNA and protein expression of APN, while inhibiting adipogenesis in 3T3-L1 adipocytes. APN-LNP enhanced osteogenic gene expression in MC3T3-E1 cells in a dose-dependent manner. It also reduced matrix metalloproteinase 9 expression in receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated RAW264.7 cells, suggesting an anti-resorptive effect. In vivo, a femoral fracture model was established to explore the application of APN-LNP in promoting bone healing in diet-induced obese mice. Micro-computed tomography and histology analysis indicated that intravenous injection with APN-LNP promoted bone healing. Fasting blood glucose and body weight were decreased in the APN-LNP group. Moreover, APN-LNP increased bone sialoprotein and runt-related transcription factor 2 expression in contralateral femurs, as well as interleukin-10 expression in white adipose tissues. Thus, our study provides promising preclinical data on the potential use of APN-LNP for treating bone disorders in obesity.

7 May 2024 in Beni-Suef University Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
PDF file
RERady Elaraby
Rady Elaraby
FRFawzy Roshdy
Fawzy Roshdy
MZMariam Zaghloul
Mariam Zaghloul
ASAhmed A. E. Saad
Ahmed A. E. Saad
MMMaha H. Morsi
Maha H. Morsi
HEHany A. Elghobary
Hany A. Elghobary
Background: Liver cancer (hepatocellular carcinoma “HCC”) remains a significant health issue without prompt detection and appropriate prevention. By interacting with each other, long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) can form gene regulatory networks. Specifically, we aim to determine whether the lncRNAs (HOTTIP, H19, and HOTAIR) and miRNA-152 interact in a significant manner in the progression of Hepatitis C virus (HCV) patients to HCC. This is followed by the question of whether these biomarkers can be used to diagnose and prognose noninvasively. We used online computational techniques to predict which miRNA group is likely to affect the lncRNAs being examined. This study involved 133 participants. 103 patients with HCV were included in the study, which was divided into two groups: Group I, with 65 cases of chronic liver disease without HCC, and Group II, with 38 cases of chronic liver disease with HCC. In addition, 30 healthy volunteers served as controls. In this study, a qRT-PCR was used to test gene expression. Results: A consistent reverse correlation has been observed between lncRNAs and miRNA-152 as the disease progresses. Conclusion: According to our findings, the studied biomarkers may be useful as noninvasive biomarkers for prognosis in patients with HCV Genotype 4 who develop liver cirrhosis and HCC. Many miRNAs, including miRNA-19a and miRNA-106a, may interact with lncRNAs that have been investigated in addition to miRNA-152.